Collegium Pharmaceutical, Inc. $COLL Shares Sold by Royce & Associates LP

Royce & Associates LP cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 18.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 251,153 shares of the specialty pharmaceutical company’s stock after selling 54,987 shares during the quarter. Royce & Associates LP owned approximately 0.79% of Collegium Pharmaceutical worth $11,628,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Federated Hermes Inc. grew its position in shares of Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 318 shares during the last quarter. Hantz Financial Services Inc. grew its position in shares of Collegium Pharmaceutical by 137.7% in the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of Collegium Pharmaceutical by 304.6% in the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares during the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the transaction, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Trading Down 0.3%

Shares of Collegium Pharmaceutical stock opened at $33.68 on Thursday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.74 and a fifty-two week high of $50.79. The firm has a market cap of $1.09 billion, a PE ratio of 16.51 and a beta of 0.76. The business’s fifty day moving average is $34.19 and its two-hundred day moving average is $41.50. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. Collegium Pharmaceutical’s revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.49 earnings per share. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Analysts Set New Price Targets

COLL has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a report on Tuesday, February 10th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $57.50.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.